Jenscare Scientific Co. Ltd. has announced its unaudited consolidated interim results for the six months ended June 30, 2025. The company reported a revenue of RMB 13.426 million, with no comparative revenue recorded for the same period in 2024. The cost of sales of goods was RMB 1.599 million, resulting in a gross profit of RMB 11.827 million. Research and development expenses increased to RMB 88.885 million from RMB 82.233 million in the previous year, while administrative expenses rose to RMB 57.433 million from RMB 35.291 million. Selling and distribution expenses were reported at RMB 3.844 million. Other expenses saw a significant increase to RMB 43.960 million from RMB 5.050 million in the prior year. The company reported a loss before tax of RMB 170.289 million, up from a loss of RMB 105.765 million in 2024. The loss for the period remained at RMB 170.289 million, with no income tax expense recorded. Other comprehensive income for the period, net of tax, was RMB 6.762 million, compared to a loss of RMB 2.102 million in the previous year, leading to a total comprehensive loss for the period of RMB 163.527 million, compared to RMB 107.867 million in 2024. Jenscare Scientific Co. Ltd. remains committed to achieving steady growth and aims to drive rapid revenue expansion while maintaining strict cost control, focusing on reaching breakeven and ultimately realizing high-quality profit growth.